Furthest along
4 in Phase 2
12 in Phase 1
Drugs
16
in active trials · 22 in all
Trials
26 active
50 since 2021
Drugs16
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 1/2 | 31 Dec 2026Phase 1/2 trial completes | |||
| Next date | 31 Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Multiple Myeloma, Neoplasm, Plasma Cell and 1 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 31 Dec 2026Phase 1/2 trial completes | |||
| Next date | 31 Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Multiple Myeloma, Neoplasm, Plasma Cell and 1 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 31 Dec 2026Phase 1/2 trial completes | |||
| Next date | 31 Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | B-ALL | ||||
| Open drug page | |||||
— |
Phase 2 | 31 Dec 2028Phase 2 trial completes | |||
| Next date | 31 Dec 2028 · Phase 2 trial completes | ||||
| Also tested for | Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL and 1 more | ||||
| Open drug page | |||||
— |
Phase 1 | 31 Dec 2026Phase 1 trial completes | |||
| Next date | 31 Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | Ovarian Cancer, Cervix Cancer and 3 more | ||||
| Open drug page | |||||
— |
Phase 1 | 31 Dec 2026Phase 1 trial completes | |||
| Next date | 31 Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | Advanced Lung Cancer, Gastric Cancer and 11 more | ||||
| Open drug page | |||||
In vivo CD19 CAR-T |
Phase 1 | Dec 2026Phase 1 trial completes | |||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | Non-Hodgkin Lymphoma | ||||
| Open drug page | |||||
— |
Phase 1 | 31 Mar 2027Phase 1 trial completes | |||
| Next date | 31 Mar 2027 · Phase 1 trial completes | ||||
| Also tested for | T-ALL/Lymphoma | ||||
| Open drug page | |||||
CD123 targeted CAR-NK cellsnot checked |
— |
Phase 1 | 30 Jun 2027Phase 1 trial completes | ||
| Next date | 30 Jun 2027 · Phase 1 trial completes | ||||
| Also tested for | AML (Acute Myeloid Leukemia), BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm) | ||||
| Open drug page | |||||
— |
Phase 1 | 31 Jul 2027Phase 1 trial completes | |||
| Next date | 31 Jul 2027 · Phase 1 trial completes | ||||
| Also tested for | Juvenile Dermatomyositis, Systemic Lupus Erythematosus | ||||
| Open drug page | |||||
— |
Phase 1 | 1 Nov 2027Phase 1 trial completes | |||
| Next date | 1 Nov 2027 · Phase 1 trial completes | ||||
| Also tested for | B Cell Lymphoma, Non Hodgkin Lymphoma and 4 more | ||||
| Open drug page | |||||
In vivo CAR-T, target not disclosed |
Phase 1 | 31 Dec 2027Phase 1 trial completes | |||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | 31 Dec 2027 · Phase 1 trial completes | ||||
| Also tested for | B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma and 2 more | ||||
| Open drug page | |||||
— |
Phase 1 | Apr 2028Phase 1 trial completes | |||
| Next date | Apr 2028 · Phase 1 trial completes | ||||
| Also tested for | Systemic Lupus Erythematosus | ||||
| Open drug page | |||||
In vivo CAR-T (CD19, BCMA and CD70 CARs), lentiviral |
Early Phase 1 | 30 May 2029Early Phase 1 trial completes | |||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | 30 May 2029 · Early Phase 1 trial completes | ||||
| Also tested for | Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia and 1 more | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Dermatomyositis, Juvenile, Dermatomyositis | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis and 3 more | ||||
| Open drug page | |||||
No drugs match “”.
About
- No active trial
- 6 other drugs
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021